Viatris Inc., a global healthcare company, has entered into an exclusive licensing agreement with Lexicon Pharmaceuticals Inc. for sotagliflozin in all markets outside the United States and Europe. Terms of the Agreement Under the terms of the agreement, Viatris will acquire rights to sotagliflozin in all global markets outside of the U.S. and Europe in exchange for an upfront payment to Lexicon of $25 million, and additional potential contingent payments, including regulatory milestones, s...